Abstract
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
Original language | English (US) |
---|---|
Pages (from-to) | 85-96 |
Number of pages | 12 |
Journal | Therapeutic Advances in Medical Oncology |
Volume | 7 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2015 |
Keywords
- immune checkpoint modulator
- nivolumab
- non-small cell lung cancer
- programmed death-1
- programmed death-1 ligand
ASJC Scopus subject areas
- Oncology